GLP-1 drugs have put peptides on investors’ radar, with Eli Lilly (LLY) and Novo Nordisk (NVO) leading the weight-loss market. But the investment opportunity extends beyond these treatments. According to industry figures, 36% of peptide medicine sales in 2025 came from diseases beyond obesity and diabetes, representing a market worth about $51 billion overall. Drug […]
The post What Is the Peptide Economy? Beyond the GLP-1 Boom appeared first on ETF Trends.
